Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ: SPRC )

0.4987 -0.0303 (-5.73%)
Streaming Delayed Price Updated: 3:58 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about SciSparc Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
From SciSparc Ltd
Via GlobeNewswire
Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.0 Million Private Placement for SciSparc Ltd. (NASDAQ: SPRC)
Via ACCESSWIRE
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
From SciSparc Ltd
Via GlobeNewswire
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
From SciSparc Ltd
Via GlobeNewswire
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
From SciSparc Ltd
Via GlobeNewswire
SciSparc Granted European Patent for its Core Technology
From SciSparc Ltd
Via GlobeNewswire
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces 1-for-26 Reverse Share Split
From SciSparc Ltd
Via GlobeNewswire
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
From SciSparc Ltd
Via GlobeNewswire
Aegis Capital Corp. acted as Sole Bookrunner on a $1.3 Million Underwritten Public Offering for SciSparc Ltd. (NASDAQ: SPRC)
Via ACCESSWIRE
SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering
From SciSparc Ltd
Via GlobeNewswire
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
From SciSparc Ltd
Via GlobeNewswire
SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
From SciSparc Ltd
Via GlobeNewswire
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome
From SciSparc Ltd
Via GlobeNewswire
Jeffs' Brands: SciSparc Nutraceuticals was Granted an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada
From Jeffs' Brands Ltd
Via GlobeNewswire
SciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
Topline results using the Company's SCI-110 met the trial’s primary and secondary end points, demonstrating high safety profile and reduced agitation 
From SciSparc Ltd
Via GlobeNewswire
SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP
From SciSparc Ltd
Via GlobeNewswire
SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Developed its Core Algorithm to allow suitable Modelling of Human Mitochondrial Carriers for Accelerating its Cancer Drug Discovery Program
From SciSparc Ltd
Via GlobeNewswire
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
From Clearmind Medicine Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.